Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.

[1]  S. Heymsfield,et al.  Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. , 2005, The Journal of clinical investigation.

[2]  T. Rabelink,et al.  Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy , 2005, Annals of Internal Medicine.

[3]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. , 2005, Diabetes.

[4]  D. Kleiner,et al.  Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy , 2005, Hepatology.

[5]  P. Gorden,et al.  The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. , 2005, Metabolism: clinical and experimental.

[6]  A. Volpe,et al.  Recombinant human leptin in women with hypothalamic amenorrhea. , 2004, The New England journal of medicine.

[7]  S. O’Rahilly,et al.  Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[8]  P. Gorden,et al.  Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  R. Krauss,et al.  Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Garg.  Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.

[11]  Y. Matsuzawa,et al.  Serum adiponectin and leptin levels in patients with lipodystrophies. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  N. Socci,et al.  Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. , 2004, The Journal of clinical investigation.

[13]  R. Hegele.  Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome , 2003, Trends in Endocrinology & Metabolism.

[14]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[15]  A. K. Agarwal,et al.  Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. , 2003, Diabetes care.

[16]  P. Gorden,et al.  Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  K. Petersen,et al.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.

[18]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[19]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[20]  M. Reitman,et al.  Lipoatrophy Revisited , 2000, Trends in Endocrinology & Metabolism.

[21]  R. Hegele,et al.  LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.

[23]  M. Lovett,et al.  Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. , 2000, American journal of human genetics.

[24]  K. Fujioka,et al.  Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. , 1999, JAMA.

[25]  A. Prentice,et al.  Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.

[26]  R. Hammer,et al.  Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy , 1999, Nature.

[27]  S. Klein,et al.  Radioimmunoassay of leptin in human plasma. , 1996, Clinical chemistry.

[28]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[29]  R. Devos,et al.  Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. , 1995, Science.

[30]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[31]  G Block,et al.  A data-based approach to diet questionnaire design and testing. , 1986, American journal of epidemiology.

[32]  P. Sax,et al.  Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. , 2004, Annals of internal medicine.

[33]  A. Bowcock,et al.  Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. , 2001, The Journal of clinical endocrinology and metabolism.

[34]  R. Hegele,et al.  Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. , 2000, Human molecular genetics.

[35]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[36]  M. Dunnigan,et al.  Familial lipoatrophic diabetes with dominant transmission. A new syndrome. , 1974, The Quarterly journal of medicine.